Local Experience in using Hormonal Therapies according to the UKISS Studies in the Treatment of Infantile Spasms in Hong Kong

Abstract

Infantile spasms constitute severe epileptic encephalopathy in infancy with characteristic seizure semiology and electroencephalographic patterns. Besides the spasms, the most detrimental effect is the impact on future developmental outcomes. Different treatment methods are used, but hormonal therapy is the most well-accepted method for treating infantile spasms in nontuberous sclerosis cases. After the launch of the original United Kingdom Infantile Spasms Study (UKISS) and the two follow-up articles, the regimens of hormonal therapy became more structured and the expected treatment outcomes were studied better. We would like to share our local experience using this protocol to treat patients with infantile spasms in Hong Kong with a case series of four patients.

Keywords

infantile spasm - UKISS - treatment - prednisolone - ACTH

• References

• 1 Lux AL, Edwards SW, Hancock E. , et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet 2004; 364 (9447): 1773-1778
• 2 Lux AL, Edwards SW, Hancock E. , et al; United Kingdom Infantile Spasms Study. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol 2005; 4 (11) 712-717
• 3 Darke K, Edwards SW, Hancock E. , et al; trial steering committee on behalf of participating investigators. Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial. Arch Dis Child 2010; 95 (05) 382-386
• 4 O'Callaghan FJ, Edwards SW, Alber FD. , et al; participating investigators. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol 2017; 16 (01) 33-42
• 5 Wilmshurst JM, Gaillard WD, Vinayan KP. , et al. Summary of recommendations for the management of infantile seizures: Task Force Report for the ILAE Commission of Pediatrics. Epilepsia 2015; 56 (08) 1185-1197
• 6 Stafstrom CE, Arnason BG, Baram TZ. , et al. Treatment of infantile spasms: emerging insights from clinical and basic science perspectives. J Child Neurol 2011; 26 (11) 1411-1421
• 7 Wong V. West syndrome--The University of Hong Kong experience (1970-2000). Brain Dev 2001; 23 (07) 609-615
• 8 Kwong L. Vigabatrin as first line therapy in infantile spasms: review of seven patients. J Paediatr Child Health 1997; 33 (02) 121-124
• 9 Riikonen R, Rener-Primec Z, Carmant L. , et al. Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study. Dev Med Child Neurol 2015; 57 (01) 60-67